OverviewSuggest Edit

Pharming Group is a biopharmaceutical company developing protein replacement therapies and precision medicines for the treatment of rare diseases. Its lead product, RUCONEST, is a recombinant human C1 esterase inhibitor approved for the treatment of acute hereditary angioedema (HAE) attacks.

TypePublic
Founded1988
HQLeiden, NL
Websitepharming.com

Latest Updates

Employees (est.) (Sept 2020)258
Revenue (FY, 2019)€169 M(+26%)
Share Price (Jul 2021)$11.3(+2%)
Cybersecurity ratingAMore

Key People/Management at Pharming Group

Sijmen De Vries

Sijmen De Vries

Executive Director and Chief Executive Officer
Jeroen Wakkerman

Jeroen Wakkerman

Chief Financial Officer
Bruno M. Giannetti

Bruno M. Giannetti

Member of the Board of Management and Chief Medical Officer
Mireille Sanders

Mireille Sanders

Chief Operations Officer
Stephen Toor

Stephen Toor

Chief Commercial Officer and General Manager Americas
Anne-Marie de Groot

Anne-Marie de Groot

Chief Ethics & Compliance Officer
Show more

Pharming Group Office Locations

Pharming Group has an office in Leiden
Leiden, NL (HQ)
24 Darwinweg
Leiden, NL
Vondellaan 47
Show all (2)

Pharming Group Financials and Metrics

Pharming Group Revenue

Embed Graph
View revenue for all periods
Pharming Group's revenue was reported to be €169.02 m in FY, 2019 which is a 25.1% increase from the previous period.
EUR

Revenue (FY, 2019)

169.0m

Revenue growth (FY, 2018 - FY, 2019), %

25.1%

Gross profit (FY, 2019)

147.7m

Gross profit margin (FY, 2019), %

87.4%

Net income (FY, 2019)

36.2m

EBIT (FY, 2019)

60.9m

Market capitalization (22-Jul-2021)

716.3m

Closing stock price (22-Jul-2021)

11.3

Cash (30-Sept-2020)

154.8m

EV

569.8m
Pharming Group's current market capitalization is $716.3 m.
EURFY, 2018FY, 2019

Revenue

135.1m169.0m

Revenue growth, %

25%

Cost of goods sold

22.2m21.4m

Gross profit

113.0m147.7m
Annual
EURFY, 2018FY, 2019

Cash

80.3m66.3m

Accounts Receivable

15.3m21.4m

Prepaid Expenses

1.8m2.3m

Inventories

17.3m14.5m
Quarterly
EURQ3, 2020

Cash

154.8m

Accounts Receivable

26.4m

Inventories

16.4m

Current Assets

197.6m
Annual
EURFY, 2018FY, 2019

Net Income

25.0m36.2m

Depreciation and Amortization

6.6m5.2m

Inventories

1.0m3.1m

Cash From Operating Activities

40.5m66.5m
Quarterly
EURQ3, 2019Q3, 2020

Net Income

24.1m25.6m

Depreciation and Amortization

5.3m5.1m

Inventories

5.8m(1.9m)

Cash From Operating Activities

50.0m55.3m
EURFY, 2018

Debt/Equity

1.2 x

Debt/Assets

0.3 x

Financial Leverage

3.7 x
Show all financial metrics

Pharming Group Operating Metrics

Q3, 2020

Preclinical Phase Products

1

Phase I Trials Products

2

Phase II Trials Products

1

Approval Phase Products

1
Show all operating metrics

Pharming Group Acquisitions / Subsidiaries

Company NameDateDeal Size
Broekman Instituut B.V.
Pharming Americas B.V.
Pharming B.V.
Pharming Healthcare, Inc.
Pharming Intellectual Property B.V.
Pharming Research & Development B.V.
Pharming Technologies B.V.
ProBio, Inc.

Pharming Group Revenue Breakdown

Embed Graph

Pharming Group revenue breakdown by geographic segment: 96.3% from U.S. and 3.7% from Other

Pharming Group Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Pharming Group Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Pharming Group Online and Social Media Presence

Embed Graph

Pharming Group News and Updates

Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Gene Therapy for Hereditary Angioedema

Highlights the broader potential of Orchard’s ex vivo HSC gene therapy platform approach in new and larger indications

Global Hereditary Angioedema Therapeutics Market 2018-2022: Market to Grow at a CAGR of 8.94% with BioCryst Pharmaceuticals, Cipla, CSL, Pharming Group & Shire Dominating

DUBLIN, Sept. 25, 2018 /PRNewswire/ -- The "Global Hereditary Angioedema Therapeutics Market 2018-2022" report has been added to ResearchAndMarkets.com's offering. The Global Hereditary Angioedema Therapeutics Market to grow at a CAGR of 8.94% during the period 2018-2022. The report...

Pharming Group Blogs

Pharming announces abstracts presented at The Western Society of Allergy, Asthma & Immunology (WSAAI) conference this week

Leiden, The Netherlands, 23 January 2019, Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) announced today that two abstracts were presented at The Western Society of Allergy, Asthma and Immunology (WSAAI) in Maui, Hawaii, USA on January 22-24, 2019. These presentations …

Pharming reports favourable conclusion from first investigator-initiated direct comparative real-world study of acute hereditary angioedema therapies

Treatment with recombinant therapy RUCONEST® and plasma-derived C1 treatments requires significantly less re-dosing than icatibant (Firazyr®) to resolve HAE attacks Leiden, The Netherlands, 7 December 2018: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) today acknowled…

Pharming Group reports interim financial results for the first nine months of 2018

Compared with the first nine months of 2017 (on a like-for-like basis): Product revenues up 74% to €97.7 million, operating profit up 144% to €31.0 million, net profit up 131% to 11.7 million Compared with the last quarter ended 30 June 2018: Product revenues up 30% to €38.6 million, operating profi…

Pharming reports positive data from first investigator-initiated study of rhC1-Inhibitor (RUCONEST®) in Contrast-induced Nephropathy

Primary Endpoint was met, with rhC1INH treatment reducing neutrophil gelatinase-associated lipocalin (NGAL), a widely recognized marker of acute renal damage Leiden, The Netherlands, 17 October 2018: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) today announced positi…

Pharming ontvangt Complete Response Letter van FDA

Verzoek tot aanvullende klinische onderzoeksgegevens voor profylaxe van erfelijk agio-oedeem Leiden, 19 September 2018, Pharming Group N.V. (“Pharming” of “de Onderneming”) (Euronext Amsterdam: PHARM) maakt bekend dat het een zogeheten Complete Response Letter (CRL) van de Amerikaanse Food and Drug …

Pharming Receives Complete Response Letter from FDA

Additional clinical trial data for prophylaxis of HAE requested Leiden, The Netherlands, 19 September 2018, Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) announced today that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA)…
Show more

Pharming Group Frequently Asked Questions

  • When was Pharming Group founded?

    Pharming Group was founded in 1988.

  • Who are Pharming Group key executives?

    Pharming Group's key executives are Sijmen De Vries, Jeroen Wakkerman and Bruno M. Giannetti.

  • How many employees does Pharming Group have?

    Pharming Group has 258 employees.

  • What is Pharming Group revenue?

    Latest Pharming Group annual revenue is €169 m.

  • What is Pharming Group revenue per employee?

    Latest Pharming Group revenue per employee is €655.1 k.

  • Who are Pharming Group competitors?

    Competitors of Pharming Group include Protalix BioTherapeutics, Five Prime Therapeutics and Ambrx.

  • Where is Pharming Group headquarters?

    Pharming Group headquarters is located at 24 Darwinweg, Leiden.

  • Where are Pharming Group offices?

    Pharming Group has an office in Leiden.

  • How many offices does Pharming Group have?

    Pharming Group has 2 offices.